Replimune
Business Services · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
500 Unicorn Park Dr Fl 3, Woburn, Massac...Phone Number
(339) 970-2843Website
www.replimune.comRevenue
$101.2 MillionStock Symbol
REPLIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
3
3
1
1
2
2
About Replimune
Replimune Group, based in Massachusetts, is a company specializing in cancer therapy and developing immunotherapies that focus on improving anti-tumor effects of the chosen, patient specific immunotherapy as well as the potency of the immune systems response.Explore more
Replimune Org Chart
RN
Executive Director
RB
Executive Director, Program Management & Port...
JZ
Senior Director, Manufacturing
GT
Senior Director, Corporate Quality Systems
DU
Senior Director, Clinical Science
SC
Senior Director, Regulatory Operations
CK
Director, Quality Projects & Continuous Impro...
LO
Director, Program Management
BP
Director
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Replimune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Replimune
Click to see if Replimune had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Replimune, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Replimune has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Replimune recently announced quarterly report
Product Launch: Get notified when Replimune launches new products
Funding: Get notified immidiatlly once Replimune has new funding data
Check out if Replimune is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Replimune
Compare insights from companies similar to Replimune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Replimune is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Replimune is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Replimune.
Replimune financials insights
Gather financial insights about Replimune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$30M
2017
Series B
$55M
2018
Stock Offering
$111M
2019
Stock Offering
$80M
2020
Stock Offering
$100M
Replimune Tech Stack
A closer look at the technologies used by Replimune
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Replimune News & Media
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026Deadline Alert: Replimune Group, Inc. (REPL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming October 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. ("Replimune" or the "Company") (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026 inclusive (the “Class Period”).Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WOBURN, Mass., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to Michelle DiNapoli, the Company’s Chief Commercial Officer.REPL Shareholder Alert: Replimune Group, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
Replimune shareholders who bought REPL stock between October 20, 2025 and April 10, 2026 retain specific rights under the federal securities laws after the FDA's rejection of the RP1 biologics license application allegedly erased more than 80% of the stock's Class Period value Replimune shareholders who bought REPL stock between October 20, 2025 and April 10, 2026 retain specific rights under the federal securities laws after the FDA's rejection of the RP1 biologics license application
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Replimune
Sign Up For FreeTo access detailed company insights
Replimune Group, based in Massachusetts, is a company specializing in cancer therapy and developing immunotherapies that focus on improving anti-tumor effects of the chosen, patient specific immunotherapy as well as the potency of the immune systems response.... Read More
